SKYE
MaterialsSkye Bioscience, Inc. Common Stock
Live · XNAS · May 9, Close
What's Moving SKYE Today?
No stock-specific AI insight has been generated for SKYE yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
SKYE News
20 articles- Skye Bioscience Presenting at GLP-1-Based Therapeutics SummitYahoo Finance·Apr 7, 2026
- Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination DevelopmentYahoo Finance·Apr 2, 2026
- Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at ConferenceMarketbeat·Mar 18, 2026
- Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ...Yahoo Finance·Mar 12, 2026
- Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 10, 2026
- Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026Yahoo Finance·Mar 5, 2026
- HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCEYahoo Finance·Feb 17, 2026
- Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With SemaglutideYahoo Finance·Feb 2, 2026
- Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity ConferenceYahoo Finance·Jan 29, 2026
- Skye Bioscience to Present Poster at Keystone Obesity ConferenceYahoo Finance·Jan 21, 2026
- Skye Provides 2026 Corporate OutlookYahoo Finance·Jan 12, 2026
- Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite RiskyYahoo Finance·Jan 12, 2026
- A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Obesity Partnership With Skye BioscienceYahoo Finance·Jan 7, 2026
- Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for ObesityYahoo Finance·Jan 5, 2026
- Skye Bioscience to Participate in Upcoming Investment ConferencesYahoo Finance·Nov 24, 2025
- ObesityWeek 2025: Breakthrough Results Reshaping the Obesity Market Landscape | DelveInsightYahoo Finance·Nov 13, 2025
- Skye Bioscience Inc (SKYE) Q3 2025 Earnings Call Highlights: Promising Study Results and ...Yahoo Finance·Nov 11, 2025
- Skye Bioscience Reports Third Quarter 2025 Financial Results and Business UpdateYahoo Finance·Nov 10, 2025
- Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight GainYahoo Finance·Nov 5, 2025
- Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025Yahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Skye Bioscience, Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.